| Dermatology and Skin Diseases | Lifetime | 30 | JP 1 | 99.76 |
| Allergic Rhinitis and Sensitization | Lifetime | 53 | JP 1 | 99.64 |
| Urticaria and Related Conditions | Lifetime | 51 | JP 3 | 99.30 |
| Asthma and respiratory diseases | Lifetime | 211 | JP 2 | 99.41 |
| Immunotherapy and Immune Responses | Lifetime | 526 | JP 14 | 99.13 |
| Food Allergy and Anaphylaxis Research | Lifetime | 150 | JP 3 | 98.77 |
| T-cell and B-cell Immunology | Lifetime | 614 | JP 23 | 98.87 |
| IL-33, ST2, and ILC Pathways | Lifetime | 163 | JP 9 | 98.35 |
| Inflammatory mediators and NSAID effects | Lifetime | 408 | JP 25 | 97.56 |
| Contact Dermatitis and Allergies | Lifetime | 236 | JP 5 | 97.89 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 276 | JP 11 | 97.76 |
| Mast cells and histamine | Lifetime | 303 | JP 35 | 96.70 |
| Autoimmune Bullous Skin Diseases | Lifetime | 399 | JP 36 | 97.16 |
| Drug-Induced Adverse Reactions | Lifetime | 470 | JP 22 | 94.39 |
| NF-κB Signaling Pathways | Lifetime | 702 | JP 68 | 94.35 |
| Skin and Cellular Biology Research | Lifetime | 548 | JP 42 | 93.87 |
| Hypertrophic osteoarthropathy and related conditions | Lifetime | 40 | JP 6 | 83.95 |
| Dermatology and Skin Diseases | 2021-2025 | 18 | JP 1 | 99.69 |
| Allergic Rhinitis and Sensitization | 2021-2025 | 22 | JP 1 | 99.51 |
| Asthma and respiratory diseases | 2021-2025 | 46 | JP 1 | 99.41 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 35 | JP 1 | 97.28 |
| Urticaria and Related Conditions | 2021-2025 | 53 | JP 2 | 97.53 |
| Food Allergy and Anaphylaxis Research | 2021-2025 | 116 | JP 4 | 96.97 |
| Mast cells and histamine | 2021-2025 | 124 | JP 7 | 91.29 |
| Immune Response and Inflammation | 2021-2025 | 483 | JP 17 | 82.98 |
| Contact Dermatitis and Allergies | 2021-2025 | 353 | JP 13 | 83.71 |
| Nail Diseases and Treatments | 2021-2025 | 616 | JP 23 | 76.72 |
| Adrenal Hormones and Disorders | 2021-2025 | 565 | JP 39 | 73.53 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 461 | JP 27 | 72.22 |
| Drug-Induced Adverse Reactions | 2021-2025 | 646 | JP 34 | 73.54 |
| Cancer and Skin Lesions | 2021-2025 | 939 | JP 70 | 64.44 |
| Genetic and rare skin diseases. | 2021-2025 | 764 | JP 38 | 34.93 |
| Dermatological and Skeletal Disorders | 2021-2025 | 893 | JP 40 | 36.54 |
| Medicine and Dermatology Studies History | 2021-2025 | 496 | JP 5 | 24.30 |
